Skip to Content
Merck
All Photos(2)

Documents

05892970001

Roche

cOmplete ULTRA Tablets, Mini, EASYpack Protease Inhibitor Cocktail

Tablets supplied in foil blister packs.

Synonym(s):

protease inhibitor

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352204
NACRES:
NA.28

form

tablet

packaging

pkg of 30 tablets (individually packed in foil blister packs)

manufacturer/tradename

Roche

solubility

water: soluble

absorption

0.4 at 280 nm (1x solution)

storage temp.

2-8°C

General description

cOmplete ULTRA Tablets contain the most powerful protease inhibitor cocktail for the optimal protection of your proteins against protease degradation. As this tablet contains EDTA, metalloproteases are also inhibited. They are supplied as tablets in an EASYpack blister pack. EASYpacks provide the most convenient form of delivery - single tablets are easily pushed through the blister foil directly into the buffer. One cOmplete ULTRA, Mini Tablet is sufficient for a volume of 10 ml extraction solution.
Recombinant proteins may be partially degraded during expression. Soluble degradation products are co-purified and cause a non-homogeneous protein preparation with protein fragments of different lengths. Metalloproteases, which are inhibited by EDTA, are fairly prevalent in, for example, bacteria.

You can easily inhibit both proteases and phosphatases at the same time by simply combining a cOmplete ULTRA, Mini, Protease Inhibitor Cocktail Tablet with a PhosSTOP Phosphatase Inhibitor Cocktail Tablet in the same 10 ml buffer.

Specificity

Inhibits serine proteases, cysteine proteases. Does not inhibit metalloproteases completely when divalent cations like Ca2+, Mg2+, or Mn2+ are present

Application

During cell lysis and purification, target proteins are at risk of being cleaved by proteases, which are naturally present in cells. To ensure that full-length proteins are obtained, cOmplete ULTRA Tablets are used for the inhibition of an extended range of proteases. This new formulation shows highest inhibition ratios due to its broadened range of inhibitors compared to standard cOmplete Tablets.
This new protease inhibitor cocktail now inhibits aspartic proteases, as well as serine, cysteine, and metalloproteases. cOmplete ULTRA Tablets were developed for maximum efficiency on different cell types. Best performance is guaranteed in lysates of bacteria, yeast, insect cells, and a wide range of higher cell lines.
Roche ′s new resin for the purification of his-tagged proteins, cOmplete His-Tag Purification Resin, is compatible with this EDTA-containing tablet. Due to a new metal ion-binding-chelator chemistry in the cOmplete His-Tag Purification Resin, EDTA can be used during Immobilized Metal Ion Affinity Chromatography (IMAC).
cOmplete ULTRA Tablets, Mini, EASYpack Protease Inhibitor Cocktail has been used as a component of radioimmunoprecipitation assay buffer (RIPA buffer). It has also been used to prevent protein degradation and coagulation in blood samples.

Features and Benefits

  • Ultra efficient protection
The extended inhibitor cocktail composition makes this tablet an ideal formulation for your most difficult, protease-sensitive targets.
  • Convenient tablet format
Eliminate weighing small amounts, and instantly protect your proteins against an exceptionally wide range of proteases by simply pushing a tablet through the EASYpack foil packaging directly into your buffers.
  • Suitable for IMAC purification
Purify poly-histidine tagged proteins.
  • Ensure laboratory safety
Avoid contact with hazardous compounds using cOmplete ULTRA Tablets.

Components

Proprietary mixture of several protease inhibitors with broad inhibitory specificity.

Physical form

Tablets in foil blister packs. Each tablet is sufficient for a volume of 10 ml extraction solution.

Preparation Note

Working concentration: 1 tablet per 10 ml extraction solution.
Working solution: Handling

Carefully push the tablet through the foil packaging using the base of your thumb (not your fingernail) to prevent the breakage of tablets.

Preparation of Working Solution

One tablet is sufficient for the inhibition of proteolytic activity in 10 ml extraction solution. If very high proteolytic activity is present, 2-3 tablets should be used for 10 ml extraction buffer. The tablets can be added directly to the extraction medium.

Stock Solution (2x conc.)

Alternatively to the direct use with lysates, a 2x stock solution can be prepared, with the following procedure:
• Add cOmplete ULTRA Tablet to 5 ml double-distilled water in a PE or PP tube.
• Vortex 3 min or until the tablet is completely dissolved.
• The stock solution is ready to use even if there are very fine parti­cles still visible in solution. These particles do not interfere with the inhibition performance of the tablets.
• Stock solution is stable for 4 weeks, stored at 2 to 8 °C, and for at least 4 weeks at  -15 to  -25 °C as well.
• During storage of the 2x stock solution, the particles can sediment. Briefly vortex the stock solution prior to use.

Storage conditions (working solution): The stock solution in water is stable for 4 weeks, stored at 2 to 8 °C, and for at least 4 weeks at  -15 to -25 °C as well.

Reconstitution

Soluble in aqueous buffers, or add directly to extraction media.

For the stock solution, use water only.

Other Notes

For life science research only. Not for use in diagnostic procedures.

Legal Information

cOmplete is a trademark of Roche

Pictograms

Corrosion

Signal Word

Danger

Hazard Statements

Hazard Classifications

Aquatic Chronic 3 - Eye Dam. 1 - Skin Corr. 1B

Storage Class Code

8A - Combustible, corrosive hazardous materials

WGK

WGK 2

Flash Point(F)

does not flash

Flash Point(C)

does not flash


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Exploiting the 7-methylimidazo [1, 5-a] pyrazin-8 (7H)-one Scaffold for the Development of Novel Chemical Inhibitors for Bromodomain and Extraterminal Domain (BET) Family
Yang Y, et al.
Bioorganic Chemistry, 103044-103044 (2019)
Yingji Li et al.
The journal of headache and pain, 22(1), 92-92 (2021-08-14)
Mutations in ATP1A2, the gene encoding the α2 subunit of Na+/K+-ATPase, are the main cause of familial hemiplegic migraine type 2 (FHM2). The clinical presentation of FHM2 with mutations in the same gene varies from pure FHM to severe forms
3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells
Chen P, et al.
Bioorganic Chemistry, 86, 119-125 (2019)
Yukiko Yasuoka et al.
Molecules (Basel, Switzerland), 27(3) (2022-02-16)
Anemia is a major complication of chronic renal failure. To treat this anemia, prolylhydroxylase domain enzyme (PHD) inhibitors as well as erythropoiesis-stimulating agents (ESAs) have been used. Although PHD inhibitors rapidly stimulate erythropoietin (Epo) production, the precise sites of Epo
Jesse J Balic et al.
Nature communications, 11(1), 3816-3816 (2020-08-01)
Detection of microbial components such as lipopolysaccharide (LPS) by Toll-like receptor 4 (TLR4) on macrophages induces a robust pro-inflammatory response that is dependent on metabolic reprogramming. These innate metabolic changes have been compared to aerobic glycolysis in tumour cells. However

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service